Dropped damages and disputed science keep the long-running talc controversy in focus
Johnson & Johnson’s long-running talc litigation has taken another turn, with a US court reducing a major damages award just as fresh doubts emerge over the science once used to defend the product’s safety.
In California, a judge struck down US$950 million in punitive damages tied to a mesothelioma case involving the company’s talc-based baby powder. However, the court allowed US$16 million in compensatory damages to stand, signalling that while the penalty was excessive, the underlying claim still carried weight.
The case is one of many facing J&J, as the company continues to battle thousands of lawsuits alleging its talc products are linked to cancers such as mesothelioma and ovarian cancer. J&J has consistently denied the claims, maintaining that its products are safe and free from asbestos.
At the same time, a new development in the scientific community is adding complexity to the issue. Medical journal The Lancet has retracted a decades-old commentary that had supported the safety of cosmetic talc. The move came after undisclosed industry ties involving the author were brought to light, raising concerns about bias.
While the commentary was not a formal research study, it had been widely referenced over the years, including in legal arguments. Its retraction now weakens a piece of evidence that has historically supported the industry’s position.
Despite this, the broader scientific landscape remains divided. Some regulators say there is not enough conclusive evidence to classify talc as carcinogenic, while others point to ongoing concerns about possible asbestos contamination.
With both legal and scientific perspectives shifting, the debate over talc safety shows no sign of settling anytime soon.
